

## DIVI'S LABORATORIES LIMITED

### UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2007 (Rs.in Lakhs)

	Particulars	STANDALONE				
		Quarter ended 31.12.2007	Quarter ended 31.12.2006	9 Months ended 31.12.2007	9 Months ended 31.12.2006	Year ended 31.03.2007
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)
1	Net Sales/Income from operations (Net of Excise Duty)	<b>28422</b>	14962	<b>75480</b>	47183	72442
2	Other Income	<b>451</b>	245	<b>949</b>	1021	1361
3	<b>Total Income:</b>	<b>28873</b>	15207	<b>76429</b>	48204	73803
4	<u>Expenditure:</u>					
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	<b>473</b>	737	<b>(2268)</b>	2105	1198
	b. Consumption of Raw Material	<b>11664</b>	5956	<b>33260</b>	21239	31112
	c. Purchase of Traded Goods	<b>0</b>	0	<b>0</b>	0	0
	d. Staff Cost	<b>1237</b>	1316	<b>3597</b>	3308	5158
	e. Depreciation	<b>906</b>	587	<b>2549</b>	1429	2233
	f. Other Expenditure					
	- Manufacturing Expenses	<b>1805</b>	1116	<b>4880</b>	3009	4381
	- Other expenses	<b>2034</b>	1583	<b>5875</b>	4312	5994
	<b>Total</b>	<b>18119</b>	11295	<b>47893</b>	35402	50076
5	Finance charges	<b>183</b>	381	<b>835</b>	651	1057
6	Exceptional items	<b>0</b>	0	<b>0</b>	0	0
7	<u>Profit from ordinary activities before Tax</u> (3-4+5+6)	<b>10571</b>	3531	<b>27701</b>	12151	22670
8	Tax Expense					
	- Current Tax (Refer to Note 3)	<b>607</b>	(23)	<b>1097</b>	2787	3332
	- Deferred Tax	<b>(112)</b>	272	<b>666</b>	272	137
	- Fringe Benefit Tax	<b>10</b>	9	<b>19</b>	16	27
9	<u>Net Profit from ordinary activities after Tax:</u> (7-8)	<b>10066</b>	3273	<b>25919</b>	9076	19174
10	Extra-ordinary items (net of tax expense)	<b>0</b>	0	<b>0</b>	0	0
11	Net Profit for the period (9-10)	<b>10066</b>	3273	<b>25919</b>	9076	19174
12	Paid-up Equity Share Capital (Face Value: Rs.2 each)	<b>1291</b>	1282	<b>1291</b>	1282	1291
13	Reserves excluding revaluation reserves					52913
14	Earnings per Share					
a)	Basic Earnings Per Share before extra-ordinary items Rs.	<b>15.59</b>	5.11	<b>40.15</b>	14.16	29.91

	Diluted Earnings Per Share before extra-ordinary items Rs.	<b>15.41</b>	5.01	<b>39.69</b>	13.89	29.55
b)	Basic Earnings Per Share after extra-ordinary items Rs.	<b>15.59</b>	5.11	<b>40.15</b>	14.16	29.91
	Diluted Earnings Per Share after extra-ordinary items Rs.	<b>15.41</b>	5.01	<b>39.69</b>	13.89	29.55
14	Aggregate of public shareholding:					
	- No. of shares	<b>29992600</b>	29528500	<b>29992600</b>	29528500	29992100
	- % of shareholding	<b>46.46%</b>	46.07%	<b>46.46%</b>	46.07%	46.46%

**NOTES:**

- The above results for the quarter and period ended 31<sup>st</sup> December 2007, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 28<sup>th</sup> January, 2008.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
- Provision for current tax for the period ended 31<sup>st</sup> December, 2007 is net of MAT Credit entitlements of Rs.1863.00 lakhs.
- The financial results for the quarter and the period ended 31<sup>st</sup> December, 2007 have been subjected to limited review carried out by the statutory auditors of the company.
- The figures for the previous year/period have been regrouped, wherever necessary.
- Consolidated Financial Results of the company with its subsidiaries M/s.Divis Laboratories (USA) Inc and M/s.Divi's Laboratories Europe AG are given below:

		Rs.lakhs				
	Particulars	Quarter ended <b>31.12.2007</b>	Quarter ended 31.12.2006	Period ended <b>31.12.2007</b>	Period ended 31.12.2006	Year Ended 31.03.2007
1	Turnover	<b>28413</b>	14951	<b>75469</b>	47192	72458
2	Net Profit after tax	<b>9906</b>	3139	<b>25492</b>	8693	18586
3	Earnings Per Share (Face Value Rs.2 each)					
	Basic: Rs.	<b>15.35</b>	4.09	<b>39.49</b>	13.56	28.99
	Diluted: Rs.	<b>15.17</b>	4.81	<b>39.03</b>	13.31	28.65

- Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.12.2007:  
Opening: Nil, Received during the Quarter: 21, Resolved: 21, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 28<sup>th</sup> January, 2008

Dr. Murali K. Divi  
Chairman & Managing Director